Recent Advancements in Multiple Myeloma

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to consider before CAR T-cell therapy.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its approval of the treatment last year.

Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung Cancer Congress.